Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All drugs

Velzatinib (IDRX-42, GSK6042981)

Stage Phase 3

Sponsor GSK (IDRx)

Route oral tablet

Modality small molecule

Class selective KIT TKI

Mechanism selective KIT tyrosine kinase inhibitor

Target KIT (TEC-0117)

Sources

publication, as of 2026-11-07

https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11501

In 2L pts, median follow-up (mFU) was 14.7 ... mo and median progression-free survival (mPFS) was 13.7 (95% CI: 7.4, 18.4) mo. In 1L ... 11 (61%) experienced unconfirmed responses ... 2L total (n=46) Objective response rate 16 (35)

J Clin Oncol 44(16_suppl) abstract 11501 (ASCO 2026), StrateGIST 1 (NCT05489237); congress abstract, preliminary

publication, as of 2026-11-07

https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS11588

Approximately 450 pts will be randomized (1:1) to receive either velzatinib (300-mg QD tablet, continuous dosing) or sunitinib (50 mg QD, 4 weeks on/2 weeks off) ... will be excluded if they have GIST that is wild type for both KIT and PDGFRA or if they have an activating PDGFRA exon 18 mutation

J Clin Oncol 44(16_suppl) TPS11588 (ASCO 2026)

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT05489237

A FIRST-IN-HUMAN (FIH) STUDY OF IDRX-42 IN PARTICIPANTS WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS (GIST)

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT07218926

A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) Versus Sunitinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib Therapy (StrateGIST 3)

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT07585266

A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) Versus Imatinib in Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

StrateGIST 1

Registry NCT05489237

Phase Phase 1

Status Active, not recruiting

Enrollment 276

Start 2022-08-03

Primary completion 2027-03-10

Study completion 2027-03-26

Catalyst Primary completion. 03.10.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Velzatinib 300 mg tablet (or 400 mg capsule), 2L

Dose 300 mg

Regimen once daily

Population 2L advanced GIST (n = 46)

Estimand Single arm

median progression-free survival: 13.7 months, median follow up 14.7 months; cutoff 12.15.2025

objective response rate: 35%, cutoff 12.15.2025

Velzatinib, 1L

Dose 300 mg

Regimen once daily

Population 1L advanced GIST (n = 18)

Estimand Single arm

unconfirmed objective response rate: 61%, median follow up 6.4 months

StrateGIST 3

Registry NCT07218926

Phase Phase 3

Status Recruiting

Enrollment 450

Start 2025-12-03

Primary completion 2028-05-30

Study completion 2030-11-29

Catalyst Primary completion. 05.30.2028. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Velzatinib 300 mg

Dose 300 mg

Regimen once daily, continuous

Comparator sunitinib 50 mg 4/2

Population GIST after imatinib; excludes KIT/PDGFRA wild type and PDGFRA exon 18

Estimand ITT

Sunitinib 50 mg 4/2

Dose 50 mg

Regimen 4 weeks on 2 off

Population GIST after imatinib

Estimand ITT

StrateGIST Frontline

Registry NCT07585266

Phase Phase 3

Status Recruiting

Enrollment 800

Start 2026-07-27

Primary completion 2032-08-30

Study completion 2032-09-28

Catalyst Primary completion. 08.30.2032. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.